Top

CNS Drugs

Published in:

01-06-2017 | Systematic Review

Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis

Authors: Gali Pariente, Tom Leibson, Talya Shulman, Thomasin Adams-Webber, Eran Barzilay, Irena Nulman

Published in: CNS Drugs | Issue 6/2017

Abstract

Introduction

Lamotrigine is used in pregnancy to control epilepsy and mood disorders. The reproductive safety of this widely used drug remains undefined and may represent a significant public health concern.

Objective

We aimed to perform a systematic review and meta-analysis of existing knowledge related to malformation rates and maternal–neonatal outcomes after in utero exposure to monotherapy with lamotrigine.

Methods

Relevant studies were identified through systematic searches conducted in MEDLINE (Ovid), Embase (Ovid), CENTRAL (Ovid), and Web of Science (Thomson Reuters) from database inception to July 2016; no language or date restrictions were applied. All publications of clinically relevant outcomes of pregnancies following in utero exposure to lamotrigine were included in this systematic review and meta-analysis.

Results

A total of 21 studies describing immediate pregnancy outcomes and rates of congenital malformations fulfilled the inclusion criteria. Compared with disease-matched controls (n = 1412, total number of patients) and healthy controls (n = 774,571, total number of patients), in utero exposure to lamotrigine monotherapy was found to be associated with significantly decreased rates of inborn defects (odds ratio [OR] 1.15; 95% confidence interval [CI] 0.62–2.16 and OR 1.25; 95% CI 0.89–1.74, respectively). Rates of miscarriages, stillbirths, preterm deliveries, and small for gestational age (SGA) neonates were not found to have been increased after in-utero exposure to LTG compared to the general population. Similarly, in utero exposure to lamotrigine monotherapy was not found to be associated with increased rates of inborn defects compared with in utero exposure to carbamazepine, and lamotrigine was found to be statistically significantly less teratogenic than valproic acid (n = 12,958 and 10,748; OR 0.84; 95% CI 0.68–1.03 and OR 0.32; 95% CI 0.26–0.39, respectively).

Conclusion

No association was found between prenatal lamotrigine monotherapy and increased rates of birth defects and other explored variables related to adverse pregnancy outcomes.

Available only for authorised users

Vajda FJE, Dodd S, Horgan D. Lamotrigine in epilepsy, pregnancy and psychiatry—a drug for all seasons? J Clin Neurosci. 2013;20(1):13–6.CrossRefPubMed

Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016–26.CrossRefPubMedPubMedCentral

Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–15.CrossRefPubMedPubMedCentral

Khan SJ, Fersh ME, Ernst C, et al. Bipolar disorder in pregnancy and postpartum: principles of management. Curr Psychiatry Rep. 2016;18(2):13.CrossRefPubMed

Tomson T, Battino D, Craig J, et al. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia. 2010;51(5):909–15.CrossRefPubMed

Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157(2):179–84.CrossRefPubMed

Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–24.CrossRefPubMed

Stewart DE, Klompenhouwer JL, Kendell RE, et al. Prophylactic lithium in puerperal psychosis. The experience of three centres. Br J Psychiatry. 1991;158:393–7.CrossRefPubMed

Wan MW, Salmon MP, Riordan DM, et al. What predicts poor mother-infant interaction in schizophrenia? Psychol Med. 2007;37(4):537–46.CrossRefPubMed

10.

Murray L, Sinclair D, Cooper P, et al. The socioemotional development of 5-year-old children of postnatally depressed mothers. J Child Psychol Psychiatry. 1999;40(8):1259–71.CrossRefPubMed

11.

O’Connor TG, Ben-Shlomo Y, Heron J, et al. Prenatal anxiety predicts individual differences in cortisol in pre-adolescent children. Biol Psychiatry. 2005;58(3):211–7.CrossRefPubMed

12.

Murray L, Fiori-Cowley A, Hooper R, et al. The impact of postnatal depression and associated adversity on early mother-infant interactions and later infant outcome. Child Dev. 1996;67(5):2512–26.CrossRefPubMed

13.

Sabers A, Dam M, Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand. 2004;109(1):9–13.CrossRefPubMed

14.

Meador KJ, Penovich P, Baker GA, et al. Antiepileptic drug use in women of childbearing age. Epilepsy Behav. 2009;15(3):339–43.CrossRefPubMedPubMedCentral

15.

Kacirova I, Grundmann M, Brozmanova H. Serum levels of lamotrigine during delivery in mothers and their infants. Epilepsy Res. 2010;91(2–3):161–5.CrossRefPubMed

16.

Hovinga CA, Pennell PB. Antiepileptic drug therapy in pregnancy II: fetal and neonatal exposure. Int Rev Neurobiol. 2008;83:241–58.CrossRefPubMed

17.

Manent JB, Jorquera I, Franco V, et al. Antiepileptic drugs and brain maturation: fetal exposure to lamotrigine generates cortical malformations in rats. Epilepsy Res. 2008;78(2–3):131–9.CrossRefPubMed

18.

Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol. 2006;2(6):1009–18.CrossRefPubMed

19.

Wilson RD, Johnson JA, Wyatt P, et al. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Canada. 2007;29(12):1003–26.CrossRef

20.

Peake JN, Copp AJ, Shawe J. Knowledge and periconceptional use of folic acid for the prevention of neural tube defects in ethnic communities in the United Kingdom: systematic review and meta-analysis. Birth Defects Res A Clin Mol Teratol. 2013;97(7):444–51.CrossRefPubMedPubMedCentral

21.

Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692–9.CrossRefPubMed

22.

Dolk H, Jentink J, Loane M, et al. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71(10):714–22.CrossRefPubMed

23.

Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA. 2011;305(19):1996–2002.CrossRefPubMed

24.

Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014;85(9):1029–34.CrossRefPubMed

25.

Margulis AV, Pladevall M, Riera-Guardia N, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014;6:359–68.CrossRefPubMedPubMedCentral

26.

Moher D, Liberati A, Tetzlaff J, et al. Reprint: preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009;89(9):873–80.PubMed

27.

Wilson RD, Davies G, Desilets V, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Canada. 2003;25(11):959–73.CrossRef

28.

Morlando M, Bhide A, Familiari A, et al. The association between prenatal atrioventricular septal defects and chromosomal abnormalities. Eur J Obstet Gynecol Reprod Biol. 2016;208:31–5.CrossRefPubMed

29.

Ban L, Fleming KM, Doyle P, et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLoS One. 2015;10(7):e0131130.CrossRefPubMedPubMedCentral

30.

Cunnington MC, Weil JG, Messenheimer JA, et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology. 2011;76(21):1817–23.CrossRefPubMed

31.

Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2008;70(22 Pt 2):2152–8.CrossRefPubMed

32.

Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006;67(3):407–12.CrossRefPubMedPubMedCentral

33.

Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77(2):193–8.CrossRefPubMed

34.

Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17.CrossRefPubMed

35.

Vajda FJ, O’Brien TJ, Lander CM, et al. The teratogenicity of the newer antiepileptic drugs: an update. Acta Neurol Scand. 2014;130(4):234–8.CrossRefPubMed

36.

Veiby G, Daltveit AK, Engelsen BA, et al. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261(3):579–88.CrossRefPubMed

37.

Cleary-Goldman J, Malone FD, Vidaver J, et al. Impact of maternal age on obstetric outcome. Obstet Gynecol. 2005;105(5 Pt 1):983–90.CrossRefPubMed

38.

Li H, Luo M, Luo J, et al. A discriminant analysis prediction model of non-syndromic cleft lip with or without cleft palate based on risk factors. BMC Pregnancy Childbirth. 2016;16(1):368.CrossRefPubMedPubMedCentral

39.

Mattson SN, Schoenfeld AM, Riley EP. Teratogenic effects of alcohol on brain and behavior. Alcohol Res Health. 2001;25(3):185–91.PubMed

40.

Hernandez-Diaz S, Mittendorf R, Smith CR, et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol. 2014;123(1):21–8.CrossRefPubMed

41.

Mawer G, Briggs M, Baker GA, et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure. 2010;19(2):112–9.CrossRefPubMed

42.

Dolk H, Wang H, Loane M, et al. Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. Neurology. 2016;86(18):1716–25.CrossRefPubMedPubMedCentral

43.

Almgren M, Kallen B, Lavebratt C. Population-based study of antiepileptic drug exposure in utero–influence on head circumference in newborns. Seizure. 2009;18(10):672–5.CrossRefPubMed

44.

Pennell PB, Klein AM, Baker GA, et al. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012;24(4):449–56.CrossRefPubMedPubMedCentral

45.

Tomson T, Battino D, Bonizzoni E, et al. Antiepileptic drugs and intrauterine death. A prospective observational study from EURAP. Neurology. 2015;85(7):580–8.CrossRefPubMed

46.

Holmes LB, Mittendorf R, Shen A, et al. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol. 2011;68(10):1275–81.CrossRefPubMed

47.

Miskov S, Gjergja Juraski R, Fucic A, et al. Prospective surveillance of croatian pregnant women under lamotrigine monotherapy: Aspects of prepregnancy counseling and drug monitoring. Epilepsia. 2009;50:109.

48.

Arkilo D, Hanna J, Dickens D, et al. Pregnancy and neurodevelopmental outcomes with in-utero antiepileptic agent exposure. A pilot study. Eur J Paediatr Neurol. 2015;19(1):37–40.CrossRefPubMed

49.

Miskov S, Gjergja-Juraski R, Cvitanovic-Sojat L, et al. Prospective surveillance of Croatian pregnant women on lamotrigine monotherapy: aspects of pre-pregnancy counseling and drug monitoring. Acta Clin. 2009;48(3):271–81.

50.

Farmen AH, Grundt J, Tomson T, et al. Intrauterine growth retardation in foetuses of women with epilepsy. Seizure. 2015;28:76–80.CrossRefPubMed

51.

Wilcox AJ, Weinberg CR, O’Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med. 1988;319(4):189–94.CrossRefPubMed

52.

Wang X, Chen C, Wang L, et al. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril. 2003;79(3):577–84.CrossRefPubMed

53.

Wyatt PR, Owolabi T, Meier C, et al. Age-specific risk of fetal loss observed in a second trimester serum screening population. Am J Obstet Gynecol. 2005;192(1):240–6.CrossRefPubMed

54.

Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1725–74.

55.

MacDorman MF, Gregory EC. Fetal and perinatal mortality: United States, 2013. Natl Vital Stat Rep. 2015;64(8):1–24.

56.

Battaglia FC, Lubchenco LO. A practical classification of newborn infants by weight and gestational age. J Pediatr. 1967;71(2):159–63.CrossRefPubMed

57.

Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162–72.CrossRefPubMed

58.

McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66(4):444–9.CrossRefPubMed

59.

Tanoshima M, Kobayashi T, Tanoshima R, et al. Risks of congenital malformations in offspring exposed to valproic acid in utero: a systematic review and cumulative meta-analysis. Clin Pharmacol Ther. 2015;98(4):417–41.CrossRefPubMed

60.

Storz-Pfennig P. Potentially unnecessary and wasteful clinical trial research detected in cumulative meta-epidemiological and trial sequential analysis. J Clin Epidemiol. 2017;82:61–70.CrossRefPubMed

61.

Koo J, Zavras A. Antiepileptic drugs (AEDs) during pregnancy and risk of congenital jaw and oral malformation. Oral Dis. 2013;19(7):712–20.CrossRefPubMed

Title: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis
Authors: Gali Pariente
Tom Leibson
Talya Shulman
Thomasin Adams-Webber
Eran Barzilay
Irena Nulman
Publication date: 01-06-2017
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 6/2017
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.1007/s40263-017-0433-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis

Abstract

Introduction

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2017

Cariprazine: A Review in Schizophrenia

Erratum to: Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD)

Cell Therapy for Multiple Sclerosis

Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis

Antimicrobial Use in Patients with Dementia: Current Concerns and Future Recommendations

Impact of Muscarinic M3 Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study